Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (Nasdaq: CAPR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics, primarily for Duchenne muscular dystrophy (DMD). Its lead product candidate is deramiocel (CAP-1002). The company has no approved commercial products and relies on equity financings, government grants, and collaboration payments for funding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $2.26 million | $6.19 million | $11.14 million | $13.09 million |
| Net Loss | $(12.56) million | $(6.39) million | $(33.35) million | $(21.53) million |
| Loss Per Share (Basic/Diluted) | $(0.38) | $(0.25) | $(1.04) | $(0.85) |
| Cash & Cash Equivalents | $68.38 million (as of Sept 30, 2024) | |||
| Marketable Securities | ||||
| Total Liquidity | $85.03 million | |||
| Working Capital | $65.35 million | |||
| Accumulated Deficit | $(192.72) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 63% in Q3 2024 compared to Q3 2023 ($2.26M vs. $6.19M). This is primarily due to the recognition of revenue from the U.S. Distribution Agreement with Nippon Shinyaku, which is recognized over time based on the progress of the HOPE-3 clinical trial. The pace of recognition slowed in the current quarter.
- Increased Operating Expenses:
- R&D Expenses: Increased 18% in Q3 ($11.81M vs. $10.03M) and 34% YTD ($35.41M vs. $26.51M). Drivers include increased headcount, expanded facility costs, and higher stock-based compensation.
- G&A Expenses: Increased 15% in Q3 ($3.46M vs. $3.02M) and 13% YTD ($10.59M vs. $9.38M), driven by personnel costs and stock-based compensation.
- Financing Activity: The company significantly bolstered its cash position through equity financing. In Q3 2024, it completed a private placement with Nippon Shinyaku raising $15.0 million. Additionally, the company fully utilized its At-The-Market (ATM) program, raising approximately $75.0 million total since inception, which closed in October 2024.
- Balance Sheet Strength: Total assets increased from $58.7 million (Dec 31, 2023) to $93.0 million (Sept 30, 2024), driven by the influx of cash from financing activities.
Guidance, Outlook, and Risks
- Regulatory Progress: The company initiated a Biologics License Application (BLA) filing in October 2024 for deramiocel to treat DMD-cardiomyopathy, based on data from the HOPE-2 and HOPE-2 OLE trials. The full submission is expected by year-end 2024.
- Clinical Trials: The HOPE-3 Phase 3 trial is ongoing. The company does not intend to unblind Cohort A in Q4 2024 as originally planned; instead, data from Cohorts A and B will be combined to support potential label expansion for skeletal muscle myopathy as a post-approval study.
- Partnerships:
- Europe: Entered a Binding Term Sheet with Nippon Shinyaku for European distribution, potentially including a $20.0 million upfront payment and up to $715.0 million in milestones.
- Exosomes: Selected for Project NextGen by the U.S. Department of Health and Human Services to advance a StealthX vaccine candidate. A Phase 1 study with NIAID is planned for Q1 2025.
- Liquidity Outlook: Management believes current cash resources ($85.0 million as of Sept 30, 2024) plus proceeds from a subsequent October 2024 public offering ($86.3 million gross) will fund operations for at least the next 12 months.
- Risks:
- Dependence on successful clinical outcomes and regulatory approvals for deramiocel.
- Need for additional capital to fund operations and commercialization; inability to raise funds could force delays or termination of programs.
- Significant operating losses and negative cash flows from operations.
- Reliance on third-party manufacturers and CROs.
Investor Verification Checklist
- BLA Submission Status: Verify the timeline and acceptance of the BLA filing for deramiocel initiated in October 2024.
- HOPE-3 Trial Data: Monitor the status of the HOPE-3 Phase 3 trial and the decision regarding the unblinding of Cohort A.
- European Agreement: Confirm the execution of the definitive agreement with Nippon Shinyaku for the European territory and the receipt of the potential $20.0 million upfront payment.
- Cash Burn Rate: Track quarterly cash usage to validate the 12-month liquidity runway estimate, especially given the high R&D spend ($35.4M YTD).
- Subsequent Offering: Confirm the net proceeds from the October 2024 underwritten public offering ($86.3M gross) and its impact on share count and dilution.